Products / Oncology & Hematology
Comprehensive Genomic Profiling
Comprehensive Genomic Profiling (CGP) is an advanced analytical approach used to gain a deep understanding of tumor biology in solid and hematologic tumors and to determine personalized treatment strategies.
Evaluating hundreds of cancer-related genes in a single test, CGP supports clinical decision-making by simultaneously analyzing biomarkers such as SNV, Indel, CNV, fusion genes, and TMB/MSI.
Applicable to samples obtained from biopsy material or liquid biopsy, this method provides a powerful tool for determining suitability for targeted therapy, clinical trial matching, and predicting treatment resistance.
Can you discover everything about the tumor from a single test?
Testing different variant types and biomarkers separately is both time-consuming and can slow down clinical decision-making processes.
Illumina TruSight Oncology 500 provides comprehensive tumor profiling by combining SNV, Indel, CNV, fusion genes, TMB, and MSI analyses in a single NGS panel.
This enables faster, more comprehensive, and clinically meaningful results.
Why isn't the best treatment the same for each patient?
Because every tumor has its own unique genetic signature. Even in patients with the same diagnosis, different molecular pathways may be active. This directly affects the response to treatment and the success of targeted approaches.
MSK-IMPACT powered by SOPHiA DDMTM analyzes over 500 cancer-related genes to detect somatic mutations with high accuracy; it supports personalized oncology approaches with the AI-powered analysis and clinical interpretation capabilities of the SOPHiA DDM platform.